These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27223685)

  • 1. Glutathione maintenance is crucial for survival of melanocytes after exposure to rhododendrol.
    Kondo M; Kawabata K; Sato K; Yamaguchi S; Hachiya A; Takahashi Y; Inoue S
    Pigment Cell Melanoma Res; 2016 Sep; 29(5):541-9. PubMed ID: 27223685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantial evidence for the rhododendrol-induced generation of hydroxyl radicals that causes melanocyte cytotoxicity and induces chemical leukoderma.
    Gabe Y; Miyaji A; Kohno M; Hachiya A; Moriwaki S; Baba T
    J Dermatol Sci; 2018 Sep; 91(3):311-316. PubMed ID: 30005897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhododendrol, a depigmentation-inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism.
    Sasaki M; Kondo M; Sato K; Umeda M; Kawabata K; Takahashi Y; Suzuki T; Matsunaga K; Inoue S
    Pigment Cell Melanoma Res; 2014 Sep; 27(5):754-63. PubMed ID: 24890809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical, cytological, and immunological mechanisms of rhododendrol-induced leukoderma.
    Tokura Y; Fujiyama T; Ikeya S; Tatsuno K; Aoshima M; Kasuya A; Ito T
    J Dermatol Sci; 2015 Mar; 77(3):146-9. PubMed ID: 25726326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-(4-hydroroxyphenyl)-2-butanol (rhododendrol) activates the autophagy-lysosome pathway in melanocytes: insights into the mechanisms of rhododendrol-induced leukoderma.
    Yang L; Yang F; Wataya-Kaneda M; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2015 Mar; 77(3):182-5. PubMed ID: 25680854
    [No Abstract]   [Full Text] [Related]  

  • 6. Depigmentation caused by application of the active brightening material, rhododendrol, is related to tyrosinase activity at a certain threshold.
    Kasamatsu S; Hachiya A; Nakamura S; Yasuda Y; Fujimori T; Takano K; Moriwaki S; Hase T; Suzuki T; Matsunaga K
    J Dermatol Sci; 2014 Oct; 76(1):16-24. PubMed ID: 25082450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and epidemiological analysis in 149 cases of rhododendrol-induced leukoderma.
    Yoshikawa M; Sumikawa Y; Hida T; Kamiya T; Kase K; Ishii-Osai Y; Kato J; Kan Y; Kamiya S; Sato Y; Yamashita T
    J Dermatol; 2017 May; 44(5):582-587. PubMed ID: 27882588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-(4-Hydroxyphenyl)-2-butanol (rhododendrol)-induced melanocyte cytotoxicity is enhanced by UVB exposure through generation of oxidative stress.
    Goto N; Tsujimoto M; Nagai H; Masaki T; Ito S; Wakamatsu K; Nishigori C
    Exp Dermatol; 2018 Jul; 27(7):754-762. PubMed ID: 29630780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zebrafish as a new model for rhododendrol-induced leukoderma.
    Hayazaki M; Hatano O; Shimabayashi S; Akiyama T; Takemori H; Hamamoto A
    Pigment Cell Melanoma Res; 2021 Nov; 34(6):1029-1038. PubMed ID: 34310852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herb Sanqi-Derived Compound K Alleviates Oxidative Stress in Cultured Human Melanocytes and Improves Oxidative-Stress-Related Leukoderma in Guinea Pigs.
    Tang S; Yang L; Kuroda Y; Lai S; Xie S; Zhang H; Katayama I
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.
    Fukaya S; Kamata M; Kasanuki T; Yokobori M; Takeoka S; Hayashi K; Tanaka T; Fukuyasu A; Ishikawa T; Ohnishi T; Iimuro S; Tada Y; Watanabe S
    J Dermatol; 2018 Nov; 45(11):1283-1288. PubMed ID: 30156328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosinase-catalyzed oxidation of rhododendrol produces 2-methylchromane-6,7-dione, the putative ultimate toxic metabolite: implications for melanocyte toxicity.
    Ito S; Ojika M; Yamashita T; Wakamatsu K
    Pigment Cell Melanoma Res; 2014 Sep; 27(5):744-53. PubMed ID: 24903082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhododendrol-induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments in comparison with vitiligo.
    Inoue S; Katayama I; Suzuki T; Tanemura A; Ito S; Abe Y; Sumikawa Y; Yoshikawa M; Suzuki K; Yagami A; Masui Y; Ito A; Matsunaga K
    J Dermatol; 2021 Jul; 48(7):969-978. PubMed ID: 33951216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Leukoderma caused by chemicals: mechanisms underlying 4-alkyl/aryl-substituted phenols- and rhododendrol-induced melanocyte loss].
    Nishimaki-Mogami T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2015; (133):13-20. PubMed ID: 26821466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical Mechanism of Rhododendrol-Induced Leukoderma.
    Ito S; Wakamatsu K
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29439519
    [No Abstract]   [Full Text] [Related]  

  • 16. Upregulation of CD86 and IL-12 by rhododendrol in THP-1 cells cocultured with melanocytes through ROS and ATP.
    Katahira Y; Sakamoto E; Watanabe A; Furusaka Y; Inoue S; Hasegawa H; Mizoguchi I; Yo K; Yamaji F; Toyoda A; Yoshimoto T
    J Dermatol Sci; 2022 Dec; 108(3):167-177. PubMed ID: 36610941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukoderma induced by rhododendrol is different from leukoderma of vitiligo in pathogenesis: A novel comparative morphological study.
    Tsutsumi R; Sugita K; Abe Y; Hozumi Y; Suzuki T; Yamada N; Yoshida Y; Yamamoto O
    J Cutan Pathol; 2019 Feb; 46(2):123-129. PubMed ID: 30456919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Use of Topical Bimatoprost on Rhododendrol-induced Refractory Leukoderma: A Case Report.
    Fukaya S; Kamata M; Kasanuki T; Yokobori M; Takeoka S; Hayashi K; Tanaka T; Fukuyasu A; Ishikawa T; Ohnishi T; Iimuro S; Watanabe S; Tada Y
    Acta Derm Venereol; 2019 Nov; 99(12):1178-1179. PubMed ID: 31449314
    [No Abstract]   [Full Text] [Related]  

  • 19. A framework to mitigate the risk of chemical leukoderma: Consumer products.
    Bjerke DL; Wu S; Wakamatsu K; Ito S; Wang J; Laughlin T; Hakozaki T
    Regul Toxicol Pharmacol; 2022 Jun; 131():105157. PubMed ID: 35292310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanocyte-specific cytotoxic T lymphocytes in patients with rhododendrol-induced leukoderma.
    Fujiyama T; Ikeya S; Ito T; Tatsuno K; Aoshima M; Kasuya A; Sakabe J; Suzuki T; Tokura Y
    J Dermatol Sci; 2015 Mar; 77(3):190-2. PubMed ID: 25724360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.